%	O
%	O
TITLE	O

Potential	O
cost	B-Study_Type
-	I-Study_Type
effectiveness	I-Study_Type
and	O
benefit	O
-	O
cost	O
ratios	O
of	O
adult	O
pneumococcal	O
vaccination	O
in	O
Germany	B-Study_Location
.	O

%	O
%	O
ABSTRACT	O

Invasive	O
(	O
IPD	B-Pneumococcal_Disease_Type
,	O
defined	O
as	O
detection	O
of	O
pneumococci	O
in	O
sterile	O
body	O
fluids	O
like	O
meningitis	B-Pneumococcal_Disease_Type
or	O
bacteremic	O
pneumonia	B-Pneumococcal_Disease_Type
)	O
and	O
non	O
-	O
invasive	O
Streptococcus	O
pneumoniae	O
infections	O
(	O
i	O
.	O
e	O
.	O
non	B-Pneumococcal_Disease_Type
-	I-Pneumococcal_Disease_Type
bacteremic	I-Pneumococcal_Disease_Type
pneumonia	I-Pneumococcal_Disease_Type
,	O
otitis	B-Pneumococcal_Disease_Type
media	I-Pneumococcal_Disease_Type
)	O
in	O
adults	O
are	O
associated	O
with	O
substantial	O
morbidity	O
,	O
mortality	O
and	O
costs	O
.	O

In	O
Germany	B-Study_Location
,	O
Pneumococcal	O
polysaccharide	O
vaccination	O
(	O
PPV23	O
)	O
is	O
recommended	O
for	O
all	O
persons	O
>	O
60â€‰years	O
and	O
for	O
defined	O
risk	O
groups	O
(	O
age	O
5	O
-	O
59	O
)	O
.	O

The	B-Study_Purpose
aim	I-Study_Purpose
of	I-Study_Purpose
this	I-Study_Purpose
model	I-Study_Purpose
was	I-Study_Purpose
to	I-Study_Purpose
estimate	I-Study_Purpose
the	I-Study_Purpose
potential	I-Study_Purpose
cost	I-Study_Purpose
-	I-Study_Purpose
effectiveness	I-Study_Purpose
and	I-Study_Purpose
benefit	I-Study_Purpose
-	I-Study_Purpose
cost	I-Study_Purpose
ratios	I-Study_Purpose
of	I-Study_Purpose
the	I-Study_Purpose
adult	I-Study_Purpose
vaccination	I-Study_Purpose
program	I-Study_Purpose
(	I-Study_Purpose
18â€‰years	I-Study_Purpose
and	I-Study_Purpose
older	I-Study_Purpose
)	I-Study_Purpose
,	I-Study_Purpose
considering	I-Study_Purpose
the	I-Study_Purpose
launch	I-Study_Purpose
of	I-Study_Purpose
the	I-Study_Purpose
pneumococcal	I-Study_Purpose
conjugate	I-Study_Purpose
vaccine	I-Study_Purpose
for	I-Study_Purpose
adults	I-Study_Purpose
(	I-Study_Purpose
PCV13	I-Study_Purpose
)	I-Study_Purpose
.	O
A	O
cross	B-Study_Type
-	I-Study_Type
sectional	I-Study_Type
steady	I-Study_Type
state	I-Study_Type
Markov	I-Study_Type
model	I-Study_Type
was	O
developed	O
to	O
estimate	O
the	O
outcomes	O
of	O
PCV13	O
,	O
PPV23	O
vaccination	O
schemes	O
and	O
'	O
no	O
vaccination	O
'	O
.	O

Conservative	O
assumptions	O
were	O
made	O
if	O
no	O
data	O
were	O
available	O
for	O
PCV13	O
and	O
PPV23	O
respectively	O
.	O

The	O
effectiveness	O
of	O
individual	O
pneumococcal	O
vaccination	O
in	O
adults	O
was	O
adjusted	O
for	O
expected	O
indirect	O
effects	O
due	O
to	O
the	O
vaccination	O
in	O
infants	O
.	O

Data	O
on	O
incidences	O
,	O
effectiveness	O
and	O
costs	O
were	O
derived	O
from	O
scientific	O
literature	O
and	O
publicly	O
available	O
databases	O
.	O

All	O
resources	O
used	O
are	O
indicated	O
.	O

Benefit	O
-	O
cost	O
ratios	O
and	O
cost	O
-	O
effectiveness	O
were	O
evaluated	O
from	O
the	O
perspective	O
of	O
the	O
German	O
Statutory	O
Health	O
Insurance	O
as	O
well	O
as	O
from	O
social	O
perspective	O
.	O
Under	O
the	O
assumption	O
that	O
PCV13	O
has	O
a	O
comparable	O
effectiveness	O
to	O
PCV7	O
,	O
a	O
vaccination	O
program	O
with	O
PCV13	O
revealed	O
the	O
potential	O
to	O
avoid	O
a	O
greater	O
number	O
of	O
yearly	O
cases	O
and	O
deaths	O
in	O
IPD	B-Pneumococcal_Disease_Type
and	O
pneumonia	B-Pneumococcal_Disease_Type
in	O
Germany	B-Study_Location
compared	O
to	O
PPV23	O
.	O

For	O
PCV13	O
,	O
the	O
costs	O
were	O
shown	O
to	O
be	O
overcompensated	O
by	O
monetary	O
savings	O
resulting	O
from	O
reduction	O
in	O
the	O
use	O
of	O
health	O
care	O
services	O
.	O

These	O
results	O
would	O
render	O
the	O
switch	O
from	O
PPV23	O
to	O
PCV13	O
as	O
a	O
dominant	O
strategy	O
compared	O
to	O
PPV23	O
and	O
'	O
no	O
vaccination	O
'	O
.	O

Given	O
the	O
correctness	O
of	O
the	O
underlying	O
assumptions	O
every	O
Euro	O
spent	O
on	O
the	O
PCV13	O
vaccination	O
scheme	O
yields	O
savings	O
of	O
2	O
.	O
09	O
â‚¬	O
(	O
social	O
perspective	O
:	O
2	O
.	O
16	O
â‚¬	O
)	O
compared	O
to	O
PPV23	O
and	O
1	O
.	O
27	O
â‚¬	O
(	O
social	O
perspective	O
:	O
1	O
.	O
32	O
â‚¬	O
)	O
compared	O
to	O
'	O
no	O
vaccination	O
'	O
,	O
respectively	O
.	O
Results	O
of	O
the	O
model	O
indicate	O
that	O
the	O
health	O
economic	O
benefit	O
of	O
immunizing	O
adults	O
with	O
PCV13	O
can	O
be	O
expected	O
to	O
outperform	O
the	O
sole	O
use	O
of	O
PPV23	O
,	O
if	O
the	O
effectiveness	O
of	O
PCV13	O
is	O
comparable	O
to	O
the	O
effectiveness	O
of	O
PCV7	O
.	O

%	O
%	O
METHODS	O

Model	O
structure	O

To	B-Study_Purpose
compare	I-Study_Purpose
the	I-Study_Purpose
benefit	I-Study_Purpose
-	I-Study_Purpose
cost	I-Study_Purpose
ratio	I-Study_Purpose
and	I-Study_Purpose
cost	I-Study_Purpose
-	I-Study_Purpose
effectiveness	I-Study_Purpose
of	I-Study_Purpose
three	I-Study_Purpose
different	I-Study_Purpose
pneumococcal	I-Study_Purpose
vaccination	I-Study_Purpose
strategies	I-Study_Purpose
(	I-Study_Purpose
PPV23	I-Study_Purpose
,	I-Study_Purpose
PCV13	I-Study_Purpose
and	I-Study_Purpose
‘no	I-Study_Purpose
vaccination’	I-Study_Purpose
)	I-Study_Purpose
in	I-Study_Purpose
adults	I-Study_Purpose
,	I-Study_Purpose
we	I-Study_Purpose

updated	I-Study_Purpose
and	I-Study_Purpose
extended	I-Study_Purpose
a	I-Study_Purpose
recently	I-Study_Purpose
developed	I-Study_Purpose
Markov	I-Study_Purpose
model	I-Study_Purpose
.	O

The	O
analysis	O
focused	O
on	O
a	O
comparison	O
between	O
a	O
PCV13	O
and	O
a	O
PPV23	O
vaccination	O
strategy	O
.	O

Therefore	O
,	O
we	O
simulated	O
a	O
setting	O
in	O
which	O
both	O
vaccination	O
programs	O
were	O
fully	O
established	O
according	O
to	O
the	O
vaccination	O
recommendations	O
in	O
Germany	O
.	O

For	O
the	O
following	O
,	O
we	O
de	O
-	O
fine	O
this	O
setting	O
,	O
in	O
which	O
all	O
new	O
entrants	O
of	O
the	O
target	O
groups	O
were	O
being	O
vaccinated	O
or	O
re	O
-	O
vaccinated	O
and	O
all	O
other	O
individuals	O
were	O
already	O
immunized	O
according	O
to	O
the	O
vaccination	O
recommendations	O
and	O
assumed	O
vaccin	O
-	O
ation	O
rates	O
,	O
as	O
a	O
steady	O
state	O
.	O

Hence	O
,	O
time	O
series	O
of	O
start	O
-	O
ing	O
and	O
establishing	O
a	O
vaccination	O
were	O
not	O
included	O
in	O
the	O
analysis	O
.	O

The	O
evaluation	O
took	O
the	O
perspective	O
of	O
the	O
German	O
Statutory	O
Health	O
Insurance	O
(	O
SHI	O
)	O
,	O
and	O
addition	O
-	O
ally	O
estimated	O
social	O
work	O
loss	O
costs	O
.	O

Outcomes	O
and	O
costs	O
of	O
each	O
vaccination	O
strategy	O
for	O
one	O
year	O
in	O
a	O
steady	O
state	O
were	O
calculated	O
in	O
two	O
steps	O
.	O

Due	O
to	O
a	O
lack	O
of	O
epidemiological	O
data	O
,	O
we	O
estimated	O
the	O
population	O
at	O
risk	O
(	O
distinguishing	O
between	O
normal	O
,	O
moderate	O
and	O
high	O
risk	O
of	O
pneumococcal	O
disease	O
)	O
in	O
83	O
age	O
groups	O
(	O
18–100	O
years	O
of	O
age	O
)	O
in	O
the	O
above	O
men	O
-	O
tioned	O
setting	O
as	O
well	O
as	O
the	O
proportion	O
of	O
immunized	O
individuals	O
due	O
to	O
vaccination	O
in	O
each	O
age	O
/	O
risk	O
group	O
using	O
a	O
Markov	O
state	O
transition	O
model	O
with	O
a	O
time	O
hori	O
-	O
zon	O
of	O
100	O
years	O
.	O

The	O
cycle	O
length	O
was	O
one	O
year	O
.	O

In	O
par	O
-	O
ticular	O
,	O
the	O
model	O
took	O
account	O
for	O
effects	O
of	O
immunized	O
individuals	O
transiting	O
to	O
other	O
risk	O
groups	O
over	O
time	O
.	O

The	O
population	O
simulation	O
started	O
with	O
healthy	O
and	O
unvac	O
-	O
cinated	O
newborns	O
developing	O
age	O
-	O
specific	O
risk	O
of	O
comor	O
-	O
bidities	O
with	O
increasing	O
age	O
which	O
are	O
associated	O
with	O
moderate	O
or	O
high	O
risk	O
of	O
pneumococcal	O
disease	O
.	O

Each	O
risk	O
group	O
got	O
vaccinated	O
according	O
to	O
the	O
strategies	O
described	O
below	O
.	O

Group	O
members	O
at	O
moderate	O
or	O
high	O
risk	O
remained	O
in	O
their	O
risk	O
group	O
during	O
the	O
simulation	O
.	O

Transition	O
to	O
death	O
was	O
possible	O
from	O
all	O
states	O
.	O

In	O
order	O
to	O
account	O
for	O
the	O
age	O
distribution	O
of	O
the	O
German	O
popu	O
-	O
lation	O
,	O
each	O
age	O
group	O
was	O
weighted	O
according	O
to	O
the	O
German	O
population	O
structure	O
in	O
the	O
year	O
2008	O
]	O
.	O

Secondly	O
,	O
for	O
the	O
modelling	O
of	O
cost	O
-	O
effectiveness	O
num	O
-	O
ber	O
of	O
cases	O
and	O
deaths	O
per	O
year	O
due	O
to	O
pneumococcal	O
diseases	O
were	O
estimated	O
for	O
each	O
vaccination	O
strategy	O
based	O
on	O
the	O
results	O
of	O
the	O
simulated	O
population	O
.	O

To	O
avoid	O
interferences	O
with	O
the	O
recently	O
published	O
children	O
model	O
,	O
children	O
and	O
adolescents	O
were	O
excluded	O
.	O

Risk	O
and	O
age	O
specific	O
morbidity	O
and	O
mortality	O
rates	O
as	O
well	O
as	O
the	O
effectiveness	O
of	O
the	O
vaccination	O
were	O
taken	O
into	O
account	O
.	O

In	O
addition	O
,	O
the	O
risk	O
model	O
calculated	O
the	O
yearly	O
costs	O
of	O
the	O
vaccination	O
programs	O
and	O
yearly	O
treatment	O
costs	O
for	O
pneumococcal	O
diseases	O
.	O

The	O
time	O
horizon	O
of	O
one	O
year	O
avoided	O
discounting	O
,	O
a	O
topic	O
of	O
high	O
relevance	O
and	O
unclear	O
positioning	O
in	O
the	O
in	O
-	O
dication	O
of	O
prevention	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
cross	O
sec	O
-	O
tional	O
design	O
of	O
the	O
model	O
neglected	O
costs	O
associated	O
with	O
the	O
implementation	O
of	O
a	O
new	O
vaccine	O
combined	O

with	O
sunk	O
costs	O
of	O
a	O
new	O
catch	O
-	O
up	O
vaccination	O
,	O
which	O
might	O
be	O
of	O
interest	O
regarding	O
the	O
budget	O
impact	O
of	O
a	O
new	O
vaccination	O
program	O
.	O

The	O
model	O
was	O
constructed	O
in	O
Microsoft	O
Excel	O
2007	O
.	O

Vaccination	O
strategies	O
/	O
choice	O
of	O
comparators	O

In	O
Germany	B-Study_Location
PPV23	O
vaccination	O
is	O
generally	O
recom	O
-	O
mended	O
for	O
adults	O
≥60	O
y	O
and	O
for	O
all	O
patients	O
>	O
5	O
y	O
with	O
comorbidities	O
and	O
increased	O
risk	O
of	O
pneumococcal	O
dis	O
-	O
ease	O
.	O

Since	O
2009	O
,	O
revaccination	O
every	O
5	O
years	O
is	O
restricted	O
to	O
patients	O
with	O
immuno	O
-	O
compromising	O
conditions	O
due	O
to	O
frequent	O
adverse	O
events	O
at	O
the	O
site	O
of	O
injection	O
and	O
questionable	O
effectiveness	O
of	O
the	O
vaccine	O

To	O
estimate	O
the	O
effects	O
of	O
PCV13	O
vaccination	O
,	O
a	O
hypo	O
-	O
thetical	O
vaccination	O
program	O
with	O
vaccinating	O
adults	O
older	O
than	O
50	O
years	O
(	O
branch	O
1	O
=	O
PCV13	O
)	O
was	O
compared	O
to	O
the	O
existing	O
PPV23	O
recommendation	O
(	O
branch	O
2	O
=	O
PPV23	O
)	O
.	O

In	O
the	O
PCV13	O
branch	O
,	O
we	O
assumed	O
that	O
adults	O
at	O
risk	O
were	O
vaccinated	O
with	O
PPV23	O
until	O
they	O
reached	O
the	O
age	O
of	O
50	O
.	O

Thereafter	O
they	O
switched	O
to	O
PCV13	O
when	O
they	O
were	O
revac	O
-	O
cinated	O
.	O

That	O
goes	O
in	O
line	O
with	O
current	O
recommendation	O
for	O
pneumococcal	O
vaccination	O
and	O
the	O
targeted	O
label	O
for	O
PCV13	O
.	O

Adults	O
developing	O
comorbidities	O
associated	O
with	O
moderate	O
or	O
high	O
risk	O
of	O
pneumococcal	O
disease	O
after	O
the	O
age	O
of	O
50	O
were	O
initially	O
and	O
revaccinated	O
with	O
PCV13	O
as	O
were	O
seniors	O
with	O
normal	O
risk	O
who	O
got	O
their	O
initial	O
vaccin	O
-	O
ation	O
at	O
the	O
age	O
of	O
60	O
,	O
analogous	O
to	O
the	O
PPV23	O
recommen	O
-	O
dation	O
.	O

For	O
PCV13	O
the	O
need	O
for	O
a	O
revaccination	O
in	O
adults	O
has	O
not	O
been	O
established	O
.	O

Nevertheless	O
we	O
assumed	O
a	O
de	O
-	O
cennial	O
booster	O
,	O
based	O
on	O
the	O
experience	O
of	O
pneumococcal	O
conjugate	O
vaccination	O
in	O
children	O
[	O
-	O
8	O
]	O
.	O

Due	O
to	O
the	O
lack	O
of	O
data	O
,	O
we	O
had	O
to	O
assume	O
vaccination	O
rates	O
for	O
initial	O
and	O
booster	O
vaccination	O
.	O

Considering	O
that	O
the	O
population	O
at	O
risk	O
gets	O
a	O
higher	O
awareness	O
,	O
ini	O
-	O
tial	O
vaccination	O
rates	O
were	O
assumed	O
to	O
be	O
higher	O
than	O
in	O
the	O
risk	O
free	O
population	O
(	O
40	O
%	O
vs	O
.	O
25	O
%	O
)	O
.	O

PPV23	O
booster	O
vaccination	O
was	O
only	O
considered	O
for	O
every	O
patient	O
in	O
the	O
high	O
risk	O
groups	O
according	O
to	O
STIKO	O
recommendations	O
In	O
contrast	O
,	O
PCV13	O
booster	O
vaccination	O
was	O
consid	O
-	O
ered	O
for	O
every	O
patient	O
at	O
risk	O
and	O
every	O
second	O
without	O
any	O
risk	O
.	O

Due	O
to	O
the	O
assumed	O
superior	O
effectiveness	O
of	O
PCV13	O
restrictions	O
regarding	O
revaccination	O
are	O
not	O
expected	O
.	O

In	O
a	O
third	O
branch	O
we	O
modelled	O
the	O
‘no	O
vaccination’	O
sce	O
-	O
nario	O
representing	O
the	O
strategy	O
not	O
to	O
prevent	O
but	O
to	O
treat	O
pneumococcal	O
disease	O
.	O

We	O
included	O
this	O
scenario	O
to	O
analyse	O
the	O
total	O
effects	O
of	O
both	O
vaccines	O
in	O
addition	O
to	O
the	O
incremental	O
effects	O
of	O
PCV13	O
versus	O
PPV23	O
.	O

Epidemiology	O

The	B-Study_Cohort
simulated	I-Study_Cohort
model	I-Study_Cohort
population	I-Study_Cohort
(	I-Study_Cohort
see	I-Study_Cohort
Figure	I-Study_Cohort
popula	I-Study_Cohort
-	I-Study_Cohort
tion	I-Study_Cohort
simulation	I-Study_Cohort
model	I-Study_Cohort
)	I-Study_Cohort
size	I-Study_Cohort
was	I-Study_Cohort
around	I-Study_Cohort
82	I-Study_Cohort
,	I-Study_Cohort
000	I-Study_Cohort
,	I-Study_Cohort
000	I-Study_Cohort
indi	I-Study_Cohort
-	I-Study_Cohort
viduals	I-Study_Cohort
representing	I-Study_Cohort
the	I-Study_Cohort
estimated	I-Study_Cohort
German	I-Study_Cohort
population	I-Study_Cohort
of	I-Study_Cohort
adults	I-Study_Cohort
in	I-Study_Cohort
2008	I-Study_Cohort
.	O

The	O
age	O
structure	O
of	O
the	O
initial	O
co	O
-	O
hort	O
and	O
the	O
number	O
of	O
patients	O
at	O
risk	O
,	O
estimated	O
according	O
to	O
data	O
of	O
Fleming	O
et	O
al	O
.	O
,	O
are	O
shown	O
in	O
Table	O
Calculation	O
of	O
life	O
expectancy	O
was	O
based	O
on	O
the	O
German	O
life	O
tables	O
from	O
2007	O
/	O
2009	O
while	O
the	O
population	O
structure	O
was	O
taken	O
from	O
the	O
German	O
Federal	O
Statistical	O
Office	O
(	O
2008	O
)	O
In	O
2008	O
,	O
the	O
overall	O
German	O
popula	O
-	O
tion	O
of	O
82	O
.	O
0	O
million	O
continued	O
to	O
decrease	O
.	O

Following	O
the	O
trend	O
of	O
recent	O
years	O
the	O
age	O
group	O
>	O
60	O
y	O
continues	O
to	O
grow	O
.	O

To	O
model	O
the	O
cost	O
-	O
effectiveness	O
,	O
a	O
population	O
size	O

Table	O
1	O
Simulated	O
population	O
size	O
(	O
total	O
population	O
)	O

*	O
Estimated	O
according	O
to	O
Fleming	O
et	O
al	O
.	O
[	O
]	O
.	O

of	O
69	O
,	O
200	O
,	O
000	O
Mio	O
was	O
used	O
(	O
age	O
18–100	O
)	O
,	O
considering	O
different	O
risk	O
groups	O
.	O

In	O
contrast	O
to	O
the	O
health	O
economic	O
endpoint	O
,	O
the	O
epi	O
-	O
demiological	O
endpoints	O
are	O
avoidable	O
episodes	O
of	O
IPD	B-Pneumococcal_Disease_Type
and	O
non	O
-	O
bacteremic	O
CAP	B-Pneumococcal_Disease_Type
in	O
an	O
inpatient	O
setting	O
as	O
well	O
as	O
in	O
an	O
outpatient	O
setting	O
.	O

Historical	O
incidences	O
for	O
IPD	B-Pneumococcal_Disease_Type
in	O
adults	O
are	O
taken	O
from	O
a	O
regional	O
surveillance	O
study	O
in	O
North	O
-	O
Rhine	O
Westphalia	O
prior	O
to	O
the	O
general	O
PCV	O
vac	O
-	O
cination	O
recommendation	O
for	O
children	O
.	O

The	O
age	O
-	O
specific	O
IPD	O
incidence	O
was	O
adjusted	O
for	O
underreporting	O
with	O
a	O
factor	O
of	O
2	O
.	O
7	O
,	O
due	O
to	O
the	O
very	O
low	O
standard	O
with	O
regard	O
to	O
the	O
collection	O
of	O
blood	O
cultures	O
in	O
Germany	B-Study_Location
.	O

The	O
burden	O
of	O
pneumococcal	O
pneumonia	B-Pneumococcal_Disease_Type
is	O
high	O
and	O
the	O
most	O
serious	O
complication	O
is	O
a	O
bacteremic	O
course	O
associated	O
with	O
a	O
high	O
case	O
fatality	O
rate	O
.	O

The	O
CAP	B-Pneumococcal_Disease_Type
inci	O
-	O
dence	O
incorporated	O
all	O
causes	O
as	O
detailed	O
microbiological	O
diagnosis	O
is	O
not	O
performed	O
on	O
a	O
regular	O
basis	O
.	O

Data	O
on	O
in	O
-	O
cidence	O
of	O
CAP	B-Pneumococcal_Disease_Type
treated	O
in	O
hospital	O
(	O
“inpatient	O
CAP”	O
)	O
are	O
based	O
on	O
the	O
German	O
hospital	O
admission	O
data	O
(	O
2008	O
)	O
.	O

The	O
BQS	O
-	O
Report	O
documented	O
that	O
200	O
,	O
000	O
CAP	O
epi	O
-	O
sodes	O
were	O
treated	O
within	O
hospital	O
every	O
year	O
,	O
which	O
is	O
very	O
close	O
to	O
the	O
numbers	O
incorporated	O
in	O
our	O
model	O
based	O
on	O
admission	O
data	O
.	O

Age	O
specific	O
incidence	O
of	O
CAP	O
treated	O
in	O
primary	O
care	O
settings	O
(	O
“outpatient	O
CAP”	O
)	O
were	O
derived	O
from	O
a	O
representative	O
pharmaceutical	O
pre	O
-	O
scription	O
panel	O
which	O
results	O
(	O
12	O
episodes	O
in	O
1	O
,	O
000	O
adults	O
)	O
were	O
similar	O
to	O
results	O
reported	O
in	O
the	O
literature	O
.	O

For	O
Schleswig	O
-	O
Holstein	O
(	O
a	O
Northern	O
region	O
in	O

Germany	O
)	O
,	O
incidence	O
of	O
CAP	O
ranged	O
between	O
3	O
.	O
7	O
and	O

12	O
.	O
3	O
cases	O
per	O
1	O
,	O
000	O
adults	O
.	O

Due	O
to	O
the	O
lack	O
of	O
valid	O
data	O
,	O
odds	O
ratios	O
for	O
IPD	B-Pneumococcal_Disease_Type
and	O
CAP	B-Pneumococcal_Disease_Type
incidences	O
in	O
moderate	O
and	O
high	O
risk	O
population	O
were	O
assumed	O
to	O
be	O
1	O
.	O
5	O
.	O

The	O
IPD	B-Pneumococcal_Disease_Type
case	O
fatality	O
rate	O
(	O
CFR	O
)	O
for	O
adults	O
was	O
taken	O
from	O
the	O
literature	O
(	O
US	O
2000–2004	O
)	O
.	O

In	O
comparison	O
,	O
the	O
German	O
CFR	O
due	O
to	O
streptococcal	O
and	O
other	O
sepsis	O
cases	O
(	O
ICD	O
A40	O
,	O
A41	O
,	O
A49	O
.	O
1	O
and	O
G00	O
.	O
1	O
)	O
in	O
the	O
age	O
groups	O
<	O
15	O
,	O
15	O
-	O
<	O
45	O
,	O
45	O
-	O
<	O
65	O
,	O
65	O
-	O
<	O
75	O
,	O
75	O
-	O
<	O
85	O
and	O
≥85	O
was	O
1	O
.	O
20	O
%	O
,	O

3	O
.	O
56	O
%	O
,	O
7	O
.	O
23	O
%	O
,	O
9	O
.	O
63	O
%	O
,	O
14	O
.	O
93	O
%	O
,	O
21	O
.	O
24	O
%	O
.	O

[	O
]	O
The	O
study	O
of	O

Dzupova	O
et	O
al	O
.	O
confirmed	O
a	O
CFR	O
for	O
adult	O
pneumococcal	O
meningitis	B-Pneumococcal_Disease_Type
of	O
20	O
%	O
.	O

The	O
6	O
months	O
CFR	O
of	O
inpatient	O
CAP	B-Pneumococcal_Disease_Type
was	O
based	O
on	O
data	O
from	O
the	O
German	O
CAPNetz	O
[	O
]	O
.	O

While	O
the	O
CFR	B-Pneumococcal_Disease_Type
in	O
CAP	B-Pneumococcal_Disease_Type
in	O
outpatient	O
settings	O
amounted	O
to	O
about	O
1	O
%	O
,	O
CFR	O
in	O
in	O
-	O
patient	O
CAP	B-Pneumococcal_Disease_Type
was	O
higher	O
(	O
see	O
Table	O
)	O
.	O

CFR	O
for	O
outpatient	O
CAP	B-Pneumococcal_Disease_Type
was	O
assumed	O
to	O
be	O
0	O
%	O
for	O
patients	O
<	O
60	O
y	O
and	O
0	O
.	O
5	O
%	O
for	O
patients	O
being	O
60y	O
and	O
older	O
.	O

Effectiveness	O

The	O
effectiveness	O
of	O
different	O
pneumococcal	O
vaccines	O
depends	O
on	O
immunization	O
level	O
,	O
vaccine	O
efficacy	O
in	O
inva	O
-	O
sive	O
and	O
non	O
-	O
invasive	O
pneumococcal	O
diseases	O
differen	O
-	O
tiated	O
to	O
age	O
and	O
risk	O
groups	O
,	O
serotype	O
coverage	O
,	O
vaccine	O
effectiveness	O
against	O
cross	O
-	O
reactive	O
serotype	O
,	O
and	O
dur	O
-	O
ation	O
of	O
protection	O
,	O
replacement	O
,	O
revaccination	O
,	O
indirect	O
(	O
herd	O
)	O
effects	O
in	O
the	O
same	O
target	O
group	O
,	O
and	O
indirect	O
(	O
herd	O
)	O
effects	O
from	O
vaccination	O
of	O
children	O
.	O

Data	O
for	O
vac	O
-	O
cine	O
efficacy	O
and	O
effectiveness	O
are	O
shown	O
in	O
Table	O

According	O
to	O
published	O
data	O
and	O
adaption	O
of	O
general	O
recommendation	O
,	O
we	O
calculated	O
IPD	B-Pneumococcal_Disease_Type
effectiveness	O
of	O
both	O
vaccines	O
using	O
efficacy	O
data	O
,	O
adjusted	O
to	O
serotype	O
distribu	O
-	O
tion	O
in	O
Germany	B-Study_Location
for	O
all	O
age	O
groups	O
.	O

For	O
PPV23	O
,	O
IPD	B-Pneumococcal_Disease_Type
data	O
were	O
derived	O
from	O
a	O
Cochrane	O
meta	O
-	O
analysis	O
reporting	O
an	O
correlate	O
IPD	B-Pneumococcal_Disease_Type
efficacy	O
of	O
74	O
%	O
(	O
with	O
no	O
present	O
statistical	O
heterogeneity	O
when	O
all	O
RCT´s	O
were	O
considered	O
)	O
.	O

However	O
,	O
the	O
reported	O
correl	O
-	O
ate	O
IPD	B-Pneumococcal_Disease_Type
efficacy	O
was	O
not	O
representative	O
for	O
subgroups	O

e	O
.	O
g	O
.	O
population	O
with	O
chronic	O
illness	O
in	O
high	O
income	O

Table	O
2	O
Incidence	O
(	O
per	O
100	O
,	O
000	O
individuals	O
)	O
and	O
Case	O
Fatality	O
Rate	O
(	O
CFR	O
)	O

}	O
including	O
a	O
factor	O
of	O
2	O
.	O
7	O
for	O
underreporting	O
(	O
29	O
)	O
,	O
#	O
assumption	O
,	O

CAP	O
:	O
community	O
acquired	O
pneumonia	O
,	O
CFR	O
:	O
case	O
fatality	O
rate	O
,	O
IPD	O
:	O
Invasive	O
Pneumococcal	O
Disease	O
.	O

Table	O
3	O
Efficacy	O
and	O
effectiveness	O
data	O
for	O
pneumococcal	O
vaccines	O

PCV13	O
PPV23	O

IPD	O

Age	O
Group	O
Efficacy	O
Serotype	O
Coverage	O
Efficacy	O
Serotype	O
Coverage	O

children	O
,	O
vaccinated	O
successfully	O
,	O
are	O
no	O
carrier	O
of	O
patho	O
-	O
gens	O
.	O

Indirect	O
effects	O
reduced	O
probability	O
of	O
infection	O
in	O
the	O
elderly	O
.	O

Evidence	O
for	O
indirect	O
effects	O
was	O
reported	O
from	O
the	O
US	O
and	O
Australia	O

Markov	O
cohort	O
models	O
are	O
not	O
able	O
to	O
directly	O
capture	O

18	O
-	O
39	O

67	O
.	O
9	O
%	O

83	O
.	O
3	O
%	O

indirect	O
herd	O
effects	O
based	O
on	O
transmission	O
dynamics	O
of	O

infectious	O
disease	O
.	O

Hence	O
,	O
we	O
included	O
one	O
additional	O
par	O
-	O

40	O
-	O
49	O
75	O
.	O
4	O
%	O
78	O
.	O
5	O
%	O

ameter	O
“herd	O
effects”	O
in	O
our	O
model	O
.	O

To	O
address	O
indirect	O

50	O
-	O
59	O

60	O
-	O
69	O

93	O
.	O
9	O
%	O
[	O
]	O
*	O

63	O
.	O
4	O
%	O

63	O
.	O
9	O
%	O

74	O
.	O
0	O
%	O
*	O
[	O
]	O

78	O
.	O
9	O
%	O

83	O
.	O
6	O
%	O

effects	O
from	O
the	O
childhood	O
vaccination	O
,	O
the	O
effectiveness	O
of	O
adult	O
vaccination	O
was	O
reduced	O
by	O
a	O
factor	O
of	O
“herd	O

70	O
-	O
79	O
71	O
.	O
4	O
%	O
78	O
.	O
3	O
%	O

80	O
-	O
89	O
74	O
.	O
8	O
%	O
84	O
.	O
5	O
%	O

≥	O
90	O
76	O
.	O
2	O
%	O
90	O
.	O
5	O
%	O

Inpatient	O
CAP	O
/	O
Outpatient	O
CAP	O
(	O
all	O
cause	O
)	O
Age	O
Group	O
Effectiveness	O
Effectiveness	O

All	O
26	O
.	O
0	O
%	O
/	O
6	O
%	O
[	O
,	O
]	O
0	O
%	O
/	O
0	O
%	O
[	O
,	O
,	O
]	O

*	O
=	O
multiplication	O
.	O

countries	O
.	O

With	O
a	O
95	O
%	O
CI	O
efficacy	O
ranges	O
overall	O
from	O
56	O
%	O
to	O
85	O
%	O
.	O

So	O
we	O
used	O
the	O
upper	O
and	O
lower	O
bound	O
for	O
sensitivity	O
analysis	O
.	O

In	O
contrast	O
,	O
the	O
reported	O
efficacy	O
data	O
for	O
CAP	B-Pneumococcal_Disease_Type
were	O
inconclusive	O
with	O
substantial	O
statistical	O
het	O
-	O
erogeneity	O
[	O
]	O
.	O

Incorporating	O
the	O
findings	O
from	O
a	O
Canadian	O
meta	O
-	O
analysis	O
[	O
the	O
conclusion	O
can	O
be	O
drawn	O
,	O
that	O
PPV23	O
does	O
not	O
appear	O
to	O
be	O
effective	O
in	O
preventing	O
CAP	B-Pneumococcal_Disease_Type
.	O

Therefore	O
,	O
we	O
assumed	O
in	O
the	O
base	O
case	O
analysis	O
that	O
PPV23	O
is	O
ineffective	O
in	O
preventing	O
CAP	B-Pneumococcal_Disease_Type
.	O

We	O
abandoned	O
this	O
assumption	O
in	O
the	O
sensitivity	O
analysis	O
by	O
calculating	O
the	O
economical	O
outcomes	O
of	O
PPV23	O
effectiveness	O
against	O
inpatient	O
CAP	B-Pneumococcal_Disease_Type
according	O
to	O
Maruyama	O
et	O
al	O
.	O
[	O
]	O
.	O

For	O
PCV13	O
,	O
assumption	O
on	O
IPD	B-Pneumococcal_Disease_Type
efficacy	O
was	O
based	O
on	O
clinical	O
data	O
for	O
PCV7	O
in	O
children	O
for	O
all	O
patients	O
,	O
expect	O
-	O
ing	O
similar	O
levels	O
of	O
efficacy	O
against	O
the	O
additional	O
6	O
sero	O
-	O
types	O
which	O
are	O
not	O
included	O
in	O
PCV7	O
.	O

Serotype	O
coverage	O
was	O
calculated	O
on	O
the	O
basis	O
of	O
data	O
reported	O
by	O
Reinert	O
et	O
al	O
.	O
[	O
]	O
Effectiveness	O
of	O
initial	O
vaccination	O
on	O
inpatient	O
and	O
outpatient	O
CAP	B-Pneumococcal_Disease_Type
for	O
PCV13	O
was	O
assumed	O
to	O
be	O
26	O
%	O
and	O
6	O
%	O
,	O
respectively	O
,	O
according	O
to	O
effectiveness	O
data	O
on	O
PCV7	O
[	O
,	O
]	O
.	O

We	O
assumed	O
that	O
vaccines	O
were	O
equally	O
effective	O
against	O
all	O
vaccine	O
serotypes	O
,	O
and	O
further	O
assumed	O
that	O
effectiveness	O
of	O
revaccination	O
with	O
PCV13	O
and	O
PPV23	O
was	O
the	O
same	O
as	O
that	O
of	O
initial	O
vaccination	O
.	O

Immunization	O
due	O
to	O
vaccination	O
with	O
PCV13	O
and	O
PPV23	O
was	O
assumed	O
to	O
be	O
effective	O
for	O
10	O
years	O
and	O
5	O
years	O
,	O
respectively	O
.	O

Then	O
the	O
effects	O
wane	O
completely	O
.	O

In	O
our	O
model	O
,	O
we	O
assumed	O
that	O
childhood	O
vaccination	O
programs	O
with	O
PCV7	O
were	O
already	O
established	O
.	O

Since	O
children	O
vaccinated	O
with	O
a	O
conjugated	O
vaccine	O
are	O
un	O
-	O
likely	O
to	O
be	O
carriers	O
for	O
the	O
seven	O
vaccine	O
serotypes	O
,	O
they	O
can	O
no	O
longer	O
transmit	O
these	O
to	O
others	O
.	O

In	O
particular	O
,	O
eld	O
-	O
erly	O
benefit	O
from	O
this	O
indirect	O
protection	O
.	O

Vaccinated	O

effects”	O
.	O

The	O
disease	O
and	O
age	O
group	O
specific	O
values	O
for	O
this	O
correction	O
factor	O
are	O
shown	O
in	O
Table	O
The	O
figures	O
were	O
calculated	O
based	O
on	O
US	O
data	O
from	O
Ray	O
et	O
al	O
.	O
[	O
]	O
and	O
Pilishvili	O
et	O
al	O
.	O
[	O
]	O
adjusted	O
for	O
German	O
serotype	O
coverage	O
according	O
to	O
Claes	O
et	O
al	O
.	O
[	O
]	O
.	O

Effects	O
due	O
to	O
serotype	O
re	O
-	O
placement	O
were	O
not	O
included	O
.	O

In	O
contrast	O
to	O
the	O
childhood	O
PCV	O
vaccination	O
,	O
adults	O
receive	O
just	O
one	O
dose	O
of	O
vaccine	O
which	O
is	O
expected	O
to	O
be	O
insufficient	O
to	O
induce	O
any	O
herd	O
effects	O
.	O

In	O
addition	O
,	O
PPV23	O
is	O
unable	O
to	O
elicit	O
immune	O
memory	O
,	O
so	O
that	O
also	O
a	O
second	O
dose	O
of	O
vaccine	O
would	O
not	O
boost	O
antibody	O
level	O
and	O
therefore	O
would	O
not	O
cause	O
signifi	O
-	O
cant	O
herd	O
effects	O
[	O
]	O
.	O

Hence	O
,	O
herd	O
effects	O
due	O
to	O
adult	O
vaccination	O
were	O
not	O
included	O
in	O
the	O
model	O
.	O

Economic	O
parameters	O

Life	O
years	O
gained	O
(	O
LYG	O
)	O
were	O
the	O
primary	O
health	O
-	O
economic	O
endpoint	O
in	O
our	O
analysis	O
.	O

Prices	O
and	O
utilization	O
of	O
health	O
services	O
per	O
unit	O
were	O
modeled	O
separately	O
.	O

We	O
evaluated	O
the	O
resource	O
use	O
from	O
the	O
perspective	O
of	O
the	O
SHI	O
in	O
Germany	B-Study_Location
,	O
taking	O
into	O
consideration	O
patient	O
co	O
-	O
payments	O
as	O
well	O
as	O
discounts	O
for	O
medications	O
given	O
by	O
the	O
manufacturer	O
and	O
pharmacies	O
as	O
required	O
by	O
legal	O
obligations	O
in	O
Germany	B-Study_Location
.	O

In	O
addition	O
,	O
we	O
estimated	O
costs	O
from	O
a	O
social	O
perspective	O
,	O
including	O
costs	O
for	O
work	O
loss	O
and	O
patients	O
co	O
-	O
payments	O
.	O

To	O
evaluate	O
the	O
costs	O
from	O
the	O
perspective	O
of	O
the	O
SHI	O
,	O
the	O
current	O
German	O
guide	O
-	O
lines	O
for	O
the	O
valuation	O
of	O
resource	O
usage	O
were	O
applied	O
.	O

Costs	O
referred	O
to	O
the	O
year	O
2010	B-Study_Time
.	O

Costs	O
of	O
medical	O
care	O
of	O
pneumococcal	O
associated	O
infections	O

In	O
the	O
German	O
health	O
care	O
system	O
,	O
inpatient	O
treatment	O
is	O
reimbursed	O
by	O
G	O
-	O
DRG	O
and	O
outpatient	O
treatment	O
by	O

Table	O
4	O
Factor	O
for	O
correction	O
of	O
indirect	O
(	O
herd	O
)	O
effects	O

Age	O
group	O
IPD	O
CAP	O

15	O
-	O
39	O
37	O
,	O
4	O
%	O
*	O
23	O
.	O
6	O
%	O
*	O

40	O
-	O
44	O
39	O
.	O
7	O
%	O
*	O
23	O
.	O
6	O
%	O
*	O

45	O
-	O
49	O
39	O
.	O
7	O
%	O
*	O
16	O
,	O
2	O
%	O
*	O

50	O
-	O
64	O
17	O
.	O
5	O
%	O
*	O
16	O
,	O
2	O
%	O
*	O

65	O
+	O
37	O
.	O
9	O
%	O
*	O
14	O
.	O
3	O
%	O
*	O

*	O
Adjusted	O
according	O
to	O
Claes	O
et	O
al	O
.	O
for	O
German	O
serotype	O
coverage	O
based	O
on	O
IPD	B-Pneumococcal_Disease_Type
data	O
from	O
Pilishvili	O
et	O
al	O
.	O
and	O
CAP	B-Pneumococcal_Disease_Type
data	O
from	O
Ray	O
et	O
al	O
.	O
[	O
]	O
.	O

official	O
German	O
Uniform	O
Valuation	O
Scheme	O
(	O
EBM	O
)	O
.	O

Table	O
summarizes	O
the	O
costs	O
,	O
which	O
were	O
integrated	O
into	O
the	O
model	O
.	O

We	O
assumed	O
that	O
all	O
IPD	B-Pneumococcal_Disease_Type
cases	O
were	O
treated	O
in	O
hospitals	O
due	O
to	O
the	O
severity	O
of	O
invasive	O
infec	O
-	O
tion	O
.	O

Further	O
we	O
assumed	O
that	O
20	O
%	O
of	O
all	O
inpatient	O
CAP	B-Pneumococcal_Disease_Type
cases	O
took	O
a	O
more	O
severe	O
course	O
.	O

No	O
cost	O
for	O
long	O
-	O
term	O
disabilities	O
from	O
IPD	B-Pneumococcal_Disease_Type
and	O
CAP	B-Pneumococcal_Disease_Type
were	O
included	O
.	O

Inpatient	O
costs	O
were	O
derived	O
from	O
official	O
G	O
-	O
DRGs	O
codes	O
(	O
German	O
Diagnosis	O
Related	O
Groups	O
)	O
in	O
2010	O
which	O
are	O
calculated	O
based	O
on	O
resource	O
use	O
in	O
2008	O
(	O
see	O
Table	O
These	O
costs	O
are	O
lump	O
sums	O
and	O
cover	O
all	O
cost	O
per	O
case	O
which	O
includes	O
,	O
in	O
general	O
,	O
all	O
expenses	O
of	O
the	O
hospital	O
(	O
incl	O
.	O

medication	O
costs	O
)	O
.	O

The	O
G	O
-	O
DRG	O
system	O
separately	O
covers	O
the	O
specific	O
need	O
for	O
mechanical	O
venti	O
-	O
lation	O
.	O

According	O
to	O
this	O
we	O
assumed	O
13	O
%	O
and	O
11	O
%	O

cases	O
with	O
mechanical	O
ventilation	O
for	O
IPD	B-Pneumococcal_Disease_Type
and	O
mod	O
-	O
erate	O
inpatient	O
CAP	B-Pneumococcal_Disease_Type
respectively	O
.	O

For	O
severe	O
inpatient	O
CAP	B-Pneumococcal_Disease_Type
the	O
DRG	O
code	O
E77A	O
covers	O
cases	O
with	O
a	O
high	O
de	O
-	O
gree	O
on	O
co	O
-	O
morbidities	O
and	O
complex	O
intensive	O
care	O
treatment	O
.	O

Regarding	O
the	O
outpatient	O
setting	O
,	O
we	O
applied	O
the	O
offi	O
-	O
cial	O
German	O
Uniform	O
Valuation	O
Scheme	O
(	O
EBM	O
)	O
.	O

For	O
general	O
outpatient	O
physician	O
visits	O
of	O
SHI	O
-	O
insured	O
per	O
-	O
sons	O
the	O
doctors	O
are	O
reimbursed	O
via	O
capitation	O
fees	O
per	O
quarter	O
,	O
independent	O
from	O
the	O
number	O
of	O
visits	O
of	O
a	O
pa	O
-	O
tient	O
per	O
quarter	O
.	O

The	O
costs	O
of	O
outpatient	O
care	O
consisted	O
of	O
a	O
quarterly	O
capitation	O
fee	O
in	O
2010	O
:	O
6y–59y	O
30	O
.	O
84	O
€	O
(	O
EBM	O
03111	O
:	O
880	O
*	O
0	O
.	O
035048	O
)	O
>	O
60	O
y	O
35	O
.	O
74	O
€	O
(	O
EBM	O
03112	O
:	O

1020	O
*	O
0	O
.	O
035048	O
)	O
plus	O
an	O
average	O
compensation	O
for	O
pre	O
-	O
scriptions	O
of	O
23	O
.	O
91	O
€	O
per	O
episode	O
generated	O
from	O
the	O
IMS	O
prescription	O
panel	O
The	O
average	O
compensa	O
-	O
tion	O
was	O
calculated	O
on	O
the	O
basis	O
of	O
prescription	O
costs	O
and	O
prescription	O
quantity	O
of	O
ICD10	O
diagnosis	O
(	O
J12–J18	O
)	O
.	O

No	O
extra	O
costs	O
for	O
treating	O
adverse	O
events	O
from	O
vaccin	O
-	O
ation	O
were	O
considered	O
in	O
the	O
model	O
.	O

Costs	O
of	O
the	O
vaccination	O
program	O

Based	O
on	O
official	O
data	O
and	O
a	O
package	O
size	O
of	O
ten	O
]	O
the	O
pharmacy	O
retail	O
price	O
of	O
PCV13	O
was	O
determined	O
to	O
be	O

64	O
.	O
62	O
€	O
per	O
dose	O
PCV13	O
and	O
28	O
.	O
94	O
€	O
per	O
dose	O
for	O
PPV23	O
.	O

There	O
is	O
no	O
official	O
rule	O
for	O
vaccine	O
pricing	O
in	O
Germany	B-Study_Location
.	O

Therefore	O
no	O
manufacturer	O
and	O
pharmacy	O
dis	O
-	O
counts	O
were	O
subtracted	O
from	O
the	O
pharmacy	O
retail	O
prices	O
for	O
vaccines	O
.	O

Based	O
on	O
a	O
sample	O
of	O
German	O
vaccination	O
agreements	O
between	O
the	O
Association	O
of	O
SHI	O
Physicians	O
and	O
the	O
SHI	O
we	O
calculated	O
an	O
average	O
reimbursement	O
fee	O
of	O
6	O
.	O
95	O
€	O
for	O
each	O
injection	O
.	O

It	O
was	O
assumed	O
that	O
the	O
vac	O
-	O
cine	O
is	O
administered	O
at	O
the	O
same	O
time	O
as	O
other	O
vaccines	O
so	O
no	O
further	O
visit	O
costs	O
are	O
incurred	O
.	O

Indirect	O
costs	O

Regarding	O
the	O
social	O
perspective	O
cost	O
of	O
work	O
loss	O
and	O
patient’s	O
co	O
-	O
payments	O
were	O
included	O
in	O
the	O
analysis	O
.	O

The	O
cost	O
of	O
work	O
loss	O
was	O
calculated	O
using	O
the	O
human	O
capital	O
approach	O
as	O
proposed	O
by	O
the	O
“Hannoveraner	O
Konsens”	O
Work	O
loss	O
was	O
expected	O
by	O
an	O
average	O
of	O
7	O
.	O
4–18	O
.	O

7	O
days	O
.	O

Table	O
5	O
Direct	O
and	O
indirect	O
cost	O
(	O
Price	O
year	O
=	O
2010	O
)	O

Non	O
-	O
medical	O
cost	O

Cost	O
for	O
work	O
disability	O
per	O
day	O
All	O
95	O
.	O
72	O
€	O
Federal	O
Statistical	O
Office	O
2010	O

Table	O
6	O
Cases	O
,	O
avoidable	O
episodes	O
and	O
deaths	O

IPD	O
Inpatient	O
CAP	O
Outpatient	O
CAP	O
total	O
Cases	O
without	O
vaccination	O

Assuming	O
an	O
age	O
specific	O
labor	O
participation	O
of	O
81	O
.	O
8	O
%	O
for	O
men	O
and	O
69	O
.	O
6	O
%	O
for	O
women	O
,	O
daily	O
cost	O
for	O
work	O
disability	O
of	O
95	O
.	O
72	O
€	O
were	O
considered	O
as	O
indirect	O

cost	O
in	O
the	O
model	O

Sensitivity	O
analysis	O

To	O
access	O
the	O
impact	O
of	O
various	O
parameters	O
on	O
model	O
outcomes	O
and	O
to	O
confirm	O
the	O
robustness	O
of	O
the	O
model	O
,	O
all	O
parameter	O
values	O
were	O
varied	O
individually	O
in	O
one	O
-	O
way	O
sensitivity	O
analysis	O
(	O
SA	O
)	O
and	O
simultaneously	O
in	O
a	O
prob	O
-	O
abilistic	O
SA	O
with	O
10	O
.	O
000	O
iterations	O
.	O

For	O
probabilistic	O
SA	O
,	O
beta	O
distributions	O
were	O
assumed	O
based	O
on	O
published	O
95	O
%	O
confidence	O
intervals	O
.	O

If	O
confidence	O
intervals	O
or	O
ranges	O
were	O
not	O
reported	O
in	O
the	O
studies	O
,	O
we	O
assumed	O
an	O
upper	O
and	O
lower	O
limit	O
of	O
±25	O
%	O
of	O
the	O
base	O
case	O
value	O
.	O

To	O
account	O
for	O
skewness	O
in	O
cost	O
data	O
we	O
used	O
gamma	O
distributions	O
.	O

Means	O
and	O
standard	O
errors	O
were	O
derived	O
from	O
the	O
corre	O
-	O
sponding	O
databases	O
(	O
DRG	O
Browser	O
[	O
]	O
,	O
IMS	O
prescription	O
panel	O
[	O
]	O
)	O
.	O

Means	O
,	O
standard	O
errors	O
,	O
and	O
distributions	O
for	O
all	O
parameters	O
examined	O
in	O
the	O
probabilistic	O
sensitivity	O
analysis	O
are	O
shown	O
in	O
the	O
Appendix	O
.	O

